These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20640909)

  • 1. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus.
    Lazo L; Gil L; Lopez C; Valdes I; Marcos E; Alvarez M; Blanco A; Romero Y; Falcon V; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2010 Oct; 155(10):1587-95. PubMed ID: 20640909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice.
    Gil L; López C; Lazo L; Valdés I; Marcos E; Alonso R; Gambe A; Martín J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2009 Oct; 21(10):1175-83. PubMed ID: 19692540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
    Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
    Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice.
    Lazo L; Zulueta A; Hermida L; Blanco A; Sánchez J; Valdés I; Gil L; López C; Romero Y; Guzmán MG; Guillén G
    Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):265-71. PubMed ID: 18636968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.
    Zulueta A; Martín J; Hermida L; Alvarez M; Valdés I; Prado I; Chinea G; Rosario D; Guillén G; Guzmán MG
    Virus Res; 2006 Oct; 121(1):65-73. PubMed ID: 16781791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.
    Valdés I; Bernardo L; Gil L; Pavón A; Lazo L; López C; Romero Y; Menendez I; Falcón V; Betancourt L; Martín J; Chinea G; Silva R; Guzmán MG; Guillén G; Hermida L
    Virology; 2009 Nov; 394(2):249-58. PubMed ID: 19783271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain III of the envelope protein as a dengue vaccine target.
    Guzman MG; Hermida L; Bernardo L; Ramirez R; Guillén G
    Expert Rev Vaccines; 2010 Feb; 9(2):137-47. PubMed ID: 20109025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
    Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
    Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice.
    Hermida L; Rodríguez R; Lazo L; Bernardo L; Silva R; Zulueta A; López C; Martín J; Valdés I; del Rosario D; Guillén G; Guzmán MG
    Biotechnol Appl Biochem; 2004 Feb; 39(Pt 1):107-14. PubMed ID: 12887334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus.
    Izquierdo A; Bernardo L; Martin J; Santana E; Hermida L; Guillén G; Guzmán MG
    Virus Res; 2008 Dec; 138(1-2):135-8. PubMed ID: 18796319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
    Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
    Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
    Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
    Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
    Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
    Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.